​William Garvin, Shareholder in the firm's FDA & Biotechnology section, comments on the outcomes-based payment arrangement for a new drug to treat pediatric and young adult leukemia patients in Bloomberg BNA's "Mixed Signals on Innovative Rx Drug Pay Arrangements."